Access to cancer drugs in Canada: Looking beyond coverage decisions

Healthcare Policy

Volumn 6, Issue 3, 2011, Pages 27-35

  Chafe, Roger ^a   Culyer, Anthony ^b   Dobrow, Mark ^b   Coyte, Peter C ^a   Sawka, Carol ^b   O'Reilly, Susan ^c   Laing, Kara ^a,d   Trudeau, Maureen ^e   Smith, Sharon ^d   Hoch, Jeffrey S ^b   Morgan, Steve ^f   Peacock, Stuart ^f   Abbott, Rick ^d   Sullivan, Terrence ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Eastern Health Canada   (Canada)

^e CANCER CARE ONTARIO   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BORTEZOMIB; BUSERELIN; CAPECITABINE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EXEMESTANE; FLUDARABINE; GEMCITABINE; GOSERELIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; IRINOTECAN; LETROZOLE; LEUPRORELIN; MEGESTROL; MEGESTROL ACETATE; METHOTREXATE; OCTREOTIDE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEMOZOLOMIDE; TRASTUZUMAB;

ARTICLE; CANADA; CONTROLLED STUDY; DRUG COST; DRUG PROGRAM; GOVERNMENT; HEALTH CARE ACCESS; HUMAN;

EID: 79952904848     PISSN: None     EISSN: 17156572     Source Type: Journal    
DOI: 10.12927/hcpol.2011.22177     Document Type: Article

References (11)

1. Berry, S.R., S. Hubay, H. Soibelman and D. Martin. 2007. "The Effect of Priority Setting Decisions for New Cancer Drugs on Medical Oncologists' Practice in Ontario: A Qualitative Study." BMC Health Services Research 7: 193. doi:10.1186/1472-6963-7-193.
2. Blumenthal, D. 1994. "The Variation Phenomenon in 1994." New England Journal of Medicine 49: 27-36.
3. Brach, B. 2008 (February 13). "Cancer Treatment 'Inconsistent, Unfair': Study." National Post. Retrieved January 12, 2011. 〈http://www.nationalpost.com/news/canada/story.html?id=304099〉.
4. Canadian Cancer Society. Cancer Drug Access for Canadians, 2009. Retrieved January 12, 2011. 〈http://www.cancer.ca/Canada-wide/About%20us/ Media%20centre/CW-Media%20releases/CW-2009/~/media/CCS/ Canada%20wide/ Files%20List/English%20files%20heading/pdf%20not%20in%20publications%20section/ CANCER%20DRUG%20ACCESS%20FINAL%20-%20English.ashx〉.
5. Government of Ontario. 2010. Inter-Provincial Joint Oncology Drug Review Process. Retrieved January 12, 2011. 〈http://www.health.gov.on.ca/english/ providers/program/drugs/drug-submissions/inter-oncology-drugs.html〉.
6. Khoo, K., R. Colucci, W. Hryniuk, J. Ragaz, S. Sehdev and C. Savage. 2007. Cancer Drug Access, Part Three: The New Wave of Cancer Drugs. Report Card on Cancer in Canada. Toronto: Cancer Advocacy Coalition of Canada. Retrieved January 12, 2011. 〈http://www.canceradvocacy.ca/reportcard/2007/ Report%20Card%20on%20Cancer%20in%20Canada,%202007.pdf〉.
7. McGinn, T., P.C. Wyer, T.B. Newman, S. Keitz, R. Leipzig and G. Guyatt. 2004. "Tips for Learners of Evidence-Based Medicine: 3. Measures of Observer Variability (Kappa Statistic)." Canadian Medical Association Journal 171:1369-73. doi:10.1503/cmaj.1031981. (Pubitemid 39573841)
8. Menon, D.S., T. Stafinski and G. Stuart. 2005. "Access to Drugs for Cancer: Does Where You Live Matter?" Canadian Journal of Public Health 96(6): 454-58. (Pubitemid 41762922)
9. Priest, L. 2007 (October 5). "Getting a Grip on Effective Cancer Treatments." The Globe and Mail. Retrieved January 12, 2011. 〈http://v1.theglobeandmail.com/servlet/story/RTGAM.20071005.ont-health05/ BNStory/ontarioelection2007/LISA+PRIEST/〉.
10. Tierney, M. and B. Manns. 2008. "Optimizing the Use of Prescription Drugs in Canada through the Common Drug Review." Canadian Medical Association Journal 178: 432-35. doi:10.1503/cmaj.070713. (Pubitemid 351303287)
11. Verma, S., S. Sehdev and A.A. Joy. 2007. "Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada." Current Oncology 14 (Suppl. 1): S3-S10.